Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arjo ABARRJF 74 Equity-to-Asset is 0.50 as of Jun. 2026, which is 6% above its 10-year median of 0.47. GuruFocus rates ARRJF with a GF Score™ of 74/100 and a GF Value™ of $3.51 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 121 Medical Distribution companies, Arjo AB ranks better than 68.6% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Arjo AB's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $815 Mil. Arjo AB's Total Assets for the quarter that ended in Jun. 2026 was $1,648 Mil.
Therefore, Arjo AB's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.50.
The historical rank and industry rank for Arjo AB's Equity-to-Asset or its related term are showing as below:
ARRJF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.32 Med: 0.47 Max: 0.72
Current: 0.5
During the past 13 years, the highest Equity to Asset Ratio of Arjo AB was 0.72. The lowest was 0.32. And the median was 0.47.
ARRJF's Equity-to-Asset is ranked better than 68.6% of 121
companies
in the Medical Distribution industry
Industry Median: 0.39
vs ARRJF: 0.50
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Arjo AB Equity-to-Asset Related Terms
Arjo AB Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Arjo AB's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARRJF vs MCK, COR, CAH: Equity-to-Asset Comparison
For the Medical Distribution subindustry, Arjo AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arjo AB Equity-to-Asset vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Arjo AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Arjo AB's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Arjo AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arjo AB (ARRJF) has a Equity-to-Asset of 0.50 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Arjo AB and its competitors. This is near median its historical median of 0.47. Over the past decade, Arjo AB's Equity-to-Asset has ranged from 0.32 to 0.72. According to the industry distribution chart, Arjo AB ranks #38 out of 121 companies in the Medical Distribution industry, placing it in the top 31.4%.
Is Arjo AB's Equity-to-Asset too high?
Arjo AB's current Equity-to-Asset of 0.50 is near median its 10-year median of 0.47. Over the past 10 years, this metric has ranged from a low of 0.32 to a high of 0.72. The Medical Distribution industry median Equity-to-Asset is 0.39. Arjo AB's value of 0.50 is 28.2% above this industry median. Based on the distribution chart, Arjo AB ranks #38 out of 121 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Arjo AB has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Arjo AB's Equity-to-Asset compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Arjo AB ranks #38 out of 121 companies for Equity-to-Asset. This puts Arjo AB in the upper half of its industry. The industry median Equity-to-Asset is 0.39. Arjo AB's value of 0.50 is 28.2% above this benchmark. Historically, Arjo AB's own Equity-to-Asset has ranged from 0.32 to 0.72 over the past decade. While the company's 10-year median is 0.47 vs. the industry median of 0.39, Arjo AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Distribution company?
The median Equity-to-Asset among Medical Distribution companies is 0.39, based on 121 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arjo AB's current Equity-to-Asset of 0.50 is 28.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Arjo AB and its competitors. For the Medical Distribution industry, the median Equity-to-Asset is 0.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arjo AB's current Equity-to-Asset is 0.50, which is near median its own 10-year median of 0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arjo AB stock overvalued right now?
Based on GuruFocus' analysis, Arjo AB (ARRJF) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.51, compared to a current price of $2.93 — trading 16.5% below its estimated fair value. The current Equity-to-Asset is 0.50, which is near median its 10-year median of 0.47 and 28.2% above the Medical Distribution industry median of 0.39. Arjo AB's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Arjo AB (ARRJF), the current Equity-to-Asset is 0.50 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arjo AB (ARRJF) Overvalued in 2026?
Based on GuruFocus' analysis, Arjo AB stock appears to be undervalued.
The current stock price of $2.93 is trading 16.5% below its estimated GF Value™ of $3.51.
GuruFocus considers Arjo AB to be Modestly Undervalued.
Key valuation signals for ARRJF:
Equity-to-Asset: 0.50 (near median its 10-year median of 0.47)
GF Value™: $3.51 vs. price of $2.93 (16.5% below fair value)
Industry Position: 28.2% above the Medical Distribution median (#38 of 121)
No single metric tells the full story. See the ARRJF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arjo AB is a supplier of medical devices, services, and solutions in Sweden. It serves its services to private and public institutions with acute care and long-term care. The company's offering includes products and solutions for patient handling, hygiene, disinfection, medical beds, therapeutic surfaces, venous thromboembolism (VTE) prevention and diagnostics. The company includes segments: Global Sales, North America, Diagnostics.
74GF Score
Get the complete analysis for ARRJF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARRJF has been successfully added to your 
